157 related articles for article (PubMed ID: 31709853)
1. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
2. HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2019 Mar; 15(8):865-874. PubMed ID: 30574797
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract][Full Text] [Related]
4. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy.
Navari RM; Mosier MC
Onco Targets Ther; 2019; 12():3277-3284. PubMed ID: 31118678
[No Abstract] [Full Text] [Related]
5. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
6. Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.
Calcanes G; Vacirca JL
J Infus Nurs; 2019; 42(5):260-263. PubMed ID: 31464835
[TBL] [Abstract][Full Text] [Related]
7. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
[No Abstract] [Full Text] [Related]
8. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
9. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
10. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
12. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
Navari RM
Future Oncol; 2019 Jan; 15(3):241-255. PubMed ID: 30304952
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
14. Safety of antiemetic prophylaxis with HTX-019 as a 30-min infusion in patients with cancer: a retrospective study.
Perry TS; Dickson N; Patton JF
Future Oncol; 2020 Mar; 16(7):263-268. PubMed ID: 31984777
[No Abstract] [Full Text] [Related]
15. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
[TBL] [Abstract][Full Text] [Related]
16. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Momper JD; Heinrichs MT; Krudys K; Griebel D; Kumar S; Kim I; Mehrotra N; Mulberg AE; Garimella N; Nelson R; Reaman G; Sinha V; Yao L; Zineh I; Burckart G; Sachs H; Mulugeta Y
J Clin Pharmacol; 2020 Jun; 60(6):775-784. PubMed ID: 31967340
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
Alhifany AA; McBride A; Almutairi AR; Cheema E; Shahbar A; Alatawi Y; Alharbi AS; Babiker H; MacDonald K; Aapro M; Abraham I
Support Care Cancer; 2020 Mar; 28(3):1031-1039. PubMed ID: 31823054
[TBL] [Abstract][Full Text] [Related]
18. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract][Full Text] [Related]
20. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
